Skip to main content

REVIEW article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1468569

Progress of Research on PD-L1 Inhibitor Adebrelimab Usage in Malignant Tumors

Provisionally accepted
Pan Cheng Pan Cheng 1Jichen He Jichen He 1Pingping Cheng Pingping Cheng 2*Kaixia Chen Kaixia Chen 1*Guangyu Zhao Guangyu Zhao 1*
  • 1 Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, China
  • 2 School of Public Health, Guangxi Medical University, Nanning, Guangx, China

The final, formatted version of the article will be published soon.

    Adebrelimab is a humanized monoclonal antibody against programmed death-ligand 1 (PD-L1) and is also a novel immune checkpoint inhibitor, which has been used in the first-line treatment of extensive stage small cell lung cancer (SCLC) with its unique mechanism of action and good clinical efficacy. Significant progress has been made in the treatment of adebrelimab in other malignancies such as non-small cell lung cancer, triple-negative breast cancer, esophageal squamous cell carcinoma, and the treatment of SCLC at different stages is also being explored. Therefore, adebrelimab emerges as a promising new treatment option for patients with small cell lung cancer (SCLC) and other types of malignant tumors.

    Keywords: adebrelimab, programmed death-ligand 1, Immune checkpoint inhibitor, extensive stage small cell lung cancer, Malignant tumors

    Received: 22 Jul 2024; Accepted: 14 Nov 2024.

    Copyright: © 2024 Cheng, He, Cheng, Chen and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Pingping Cheng, School of Public Health, Guangxi Medical University, Nanning, 530021, Guangx, China
    Kaixia Chen, Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, China
    Guangyu Zhao, Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.